Blood Based Biomarkers for Lung Cancer Early Detection and Evaluation of CT Based Lesions.

摘要

The main objective of this multi-investigator, multi-site project is to evaluate, through blinded validation studies, candidate markers from genomic (mutation analysis, DNA methylation and microRNAs), proteomic (circulating proteins and autoantibodies) and metabolomic (altered glycans, metabolites and volatile organic compounds) studies that show promise for yielding blood based tests for lung cancer. Two specific blood biomarker application goals are addressed: (1) Discrimination of benign and malignant lung nodules between 5 mm to 30 mm in size identified by thoracic CT scans and (2) Detection of non-small cell lung cancer in high risk individuals up to 24 months prior to clinical diagnosis. Led by Dr. Wan Lam and Dr. Stephen Lam, the specific tasks for the project at the BCCA are: (a) generate microRNA (miRNA), methylation and gene expression profiles of tumor and matched non-malignant tissues to identify differentially expressed miRNAs and differentially methylated genes for further testing and validation in archival and prospectively collected blood samples; (b) Collect blood samples, clinical data and final diagnosis from 100 individuals with lung nodules 3 cm being evaluated with PET/CT. Within the 100 subjects evaluated for lung cancer with PET/CT imaging prior to consideration for surgical resection, paired lung tumor and adjacent non-tumor lung tissue will be collected from a subset of 40 patients.